Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von StockNews.com 

Atossa Genetics Inc diskutieren

Atossa Genetics Inc

WKN: A2JJ99 / Symbol: ATOS / Name: Atossa Genetics / Aktie / Ausrüstung & Versorgung / Micro Cap /

0,77 €
6,56 %

Einschätzung Buy
Rendite (%) 17,07 %
Kursziel 6,49
Veränderung
Endet am 26.03.26

Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Ratings data for ATOS provided by MarketBeat

Einschätzung Buy
Rendite (%) 38,38 %
Kursziel 6,32
Veränderung
Endet am 21.04.26

Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its price target raised by analysts at Ascendiant Capital Markets from $7.00 to $7.25. They now have a "buy" rating on the stock.
Ratings data for ATOS provided by MarketBeat

Einschätzung Buy
Rendite (%) 2,54 %
Kursziel 3,50
Veränderung
Endet am 05.06.26

Atossa Therapeutics, Inc. (NASDAQ: ATOS) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $4.00 price target on the stock.
Ratings data for ATOS provided by MarketBeat

Einschätzung Buy
Rendite (%) -2,54 %
Kursziel 6,55
Veränderung
Endet am 06.06.26

Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its price target raised by analysts at Ascendiant Capital Markets from $7.25 to $7.50. They now have a "buy" rating on the stock.
Ratings data for ATOS provided by MarketBeat

Einschätzung Buy
Rendite (%) 5,79 %
Kursziel 6,61
Veränderung
Endet am 22.09.26

Atossa Genetics (NASDAQ:ATOS) had its price target raised by analysts at Ascendiant Capital Markets from $7.50 to $7.75. They now have a "buy" rating on the stock.
Ratings data for ATOS provided by MarketBeat

Einschätzung Buy
Rendite (%) 14,12 %
Kursziel 6,87
Veränderung
Endet am 08.12.26

Atossa Genetics (NASDAQ:ATOS) had its price target raised by analysts at Ascendiant Capital Markets from $7.75 to $8.00. They now have a "buy" rating on the stock.
Ratings data for ATOS provided by MarketBeat